Histidine
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Histidine: From Essential Amino Acid Supplementation to Gastroparesis
One-Sentence Summary
Histidine (DrugBank DB00117) is an essential amino acid; the evidence pack contains no recorded approved indication and no market license in the reference dataset. The TxGNN model predicts a possible link to Gastroparesis, but this prediction is currently supported by 0 clinical trials and 0 publications — it rests solely on a theoretical pharmacological argument.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in this dataset (histidine is an essential amino acid; no approved-indication text or license data is available) |
| Predicted New Indication | Gastroparesis |
| TxGNN Prediction Score | 99.55% |
| Evidence Level | L5 |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for histidine is not available in this dataset. Based on known pharmacology, histidine is the metabolic precursor of histamine — it is converted to histamine via the enzyme histidine decarboxylase (HDC). Histamine, acting through H2 receptors, is known to modulate gastric acid secretion and gastrointestinal smooth-muscle motility.
The repurposing hypothesis therefore proposes an indirect link: since gastroparesis is a disorder of gastric motility, and histamine signaling participates in regulating that motility, increased histidine (and downstream histamine) availability is theorized to have some relevance to gastroparesis. However, this is a purely pharmacological inference — TxGNN’s score is high (0.9955), but no clinical trial or literature evidence currently exists to test, support, or refute this specific drug-disease relationship.
This should be read as a hypothesis-generating signal only, not as evidence of efficacy.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Safety Considerations
Please refer to the package insert for safety information.
(Note: TFDA label warnings/contraindications and DDI data are currently missing from this evidence pack — this is flagged as a blocking data gap for safety evaluation, see “To proceed” below.)
Conclusion and Next Steps
Decision: Hold
Rationale:
- The prediction has the highest TxGNN score among candidates for this drug (99.55%) but zero supporting clinical trials or literature (Evidence Level L5) — it is a computational hypothesis only, with no human or preclinical data specific to gastroparesis.
- The drug is not currently marketed and has no active license in this dataset, and core safety data (TFDA warnings, contraindications) are marked as a blocking gap, so it cannot yet pass a basic safety screen.
To proceed, the following is needed:
- TFDA label data (warnings, contraindications) — currently a blocking gap for safety review
- Confirmed mechanism-of-action data via DrugBank API
- Preclinical or observational evidence directly testing histidine/histamine pathway modulation in gastroparesis, since none currently exists
- Note for context: this evidence pack also contains a second, lower-ranked prediction (sclerosing cholangitis, TxGNN score 99.27%, Evidence Level L4) supported by 8 mechanistic publications on histamine/mast-cell signaling in biliary fibrosis. That literature suggests histamine pathway activation drives biliary injury in that disease — a directionally opposite implication (i.e., increasing histidine/histamine could worsen rather than treat a histamine-driven pathology). This raises a caution flag worth investigating before advancing any histidine-repurposing hypothesis further, including for gastroparesis.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.